Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer
Yang Shi, Jigang Chen, Bo Shi, Aihua Liu
Topics & Concepts
PembrolizumabMedicineCost effectivenessPlaceboOncologyQuality-adjusted life yearWillingness to payInternal medicineClinical trialCancerImmunotherapyAlternative medicineMicroeconomicsEconomicsPathologyRisk analysis (engineering)Cancer Immunotherapy and BiomarkersEndometrial and Cervical Cancer TreatmentsColorectal and Anal Carcinomas